Albuminuria lowering effect of dapagliflozin, exenatide and their combination in patients with type 2 diabetes: a randomised cross-over clinical trial

被引：0
|
作者：
van der Aart-van der Beek, A. B. [1 ,2 ]
Apperloo, E. [3 ]
Jongs, N. [1 ]
Rouw, D. B. [2 ]
Sjostrom, D. [4 ]
van Raalte, D. H. [5 ]
Hoogenberg, K. [2 ]
Heerspink, H. J. L. [1 ]
机构：
[1] Univ Groningen, Groningen, Netherlands
[2] Martini Hosp, Groningen, Netherlands
[3] Isala Hosp, Groningen, Netherlands
[4] AstraZeneca, Gothenburg, Sweden
[5] Amsterdam UMC, Amsterdam, Netherlands
来源：
DIABETOLOGIA | 2022年 / 65卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
750
引用
收藏
页码：S387 / S387
页数：1
相关论文
共 50 条
  • [1] Albuminuria-lowering effect of dapagliflozin, exenatide, and their combination in patients with type 2 diabetes: A randomized cross-over clinical study
    van der Aart-van Der Beek, Annemarie B.
    Apperloo, Ellen
    Jongs, Niels
    Rouw, Dennis B.
    Sjostrom, C. David
    Friedli, Iris
    Johansson, Lars
    van Raalte, Daniel H.
    Hoogenberg, Klaas
    Heerspink, Hiddo J. L.
    DIABETES OBESITY & METABOLISM, 2023, 25 (06): : 1758 - 1768
  • [2] Albuminuria lowering effect of dapagliflozin, eplerenone and their combination in patients with chronic kidney disease a randomised cross-over clinical trial
    Provenzano, M.
    Heerspink, H. J. L.
    Puchades, M.
    Garofalo, C.
    Jongs, N.
    Adreucci, M.
    De Nicola, L.
    Gorriz, J.
    DIABETOLOGIA, 2022, 65 (SUPPL 1) : S281 - S281
  • [3] Albuminuria-Lowering Effect of Dapagliflozin, Eplerenone, and their Combination in Patients with Chronic Kidney Disease: A Randomized Cross-Over Clinical Trial
    Provenzano, Michele
    Puchades, Maria Jesus
    Garofalo, Carlo
    Jongs, Niels
    D'Marco, Luis
    Andreucci, Michele
    De Nicola, Luca
    Gorriz, Jose Luis
    Heerspink, Hiddo J. L.
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2022, 33 (08): : 1569 - 1580
  • [4] Effect of dapagliflozin on circulating biomarkers of extracellular matrix remodelling in type 2 diabetes with albuminuria: a randomised clinical trial
    Wasehuus, V.
    Curovic, V. R.
    Eickhoff, M. K.
    Moller, A. L.
    Rasmussen, D. G. K.
    Genovese, F.
    Frimodt-Moller, M.
    Hansen, T. W.
    Rossing, P.
    Persson, F.
    DIABETOLOGIA, 2023, 66 (SUPPL 1) : S453 - S454
  • [5] The acute effect of hyperketonaemia on cognitive performance in patients with type 2 diabetes: a randomised cross-over trial
    Jensen, N. J.
    Nilsson, M.
    Ingerslev, J.
    Svart, M.
    Moller, N.
    Olsen, D.
    Zander, M.
    Miskowiak, K.
    Rungby, J.
    DIABETOLOGIA, 2019, 62 : S70 - S71
  • [6] Effect of dapagliflozin on renal and cardiac function in patients with type 2 diabetes and albuminuria: a randomised study
    Eickhoff, M. K.
    Olsen, F. J.
    Frimodt-Moller, M.
    Diaz, L. J.
    Jensen, M. T.
    Rossing, P.
    Persson, F.
    DIABETOLOGIA, 2018, 61 : S299 - S300
  • [7] EFFECT OF DAPAGLIFLOZIN ON ALBUMINURIA IN PATIENTS WITH TYPE 2 DIABETES AND CKD
    Abdullaev, Sherzod
    Sharapov, Olimkhon
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2023, 38 : I685 - I686
  • [8] Albuminuria Responses to Dapagliflozin in Patients With Type 2 Diabetes A Crossover Trial
    Beernink, Jelle M.
    Jongs, Niels
    Doelman, Cees J. A.
    Laverman, Gozewijn D.
    Heerspink, Hiddo J. L.
    JAMA NETWORK OPEN, 2025, 8 (03)
  • [9] Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial
    Pollock, Carol
    Stefansson, Bergur
    Reyner, Daniel
    Rossing, Peter
    Sjostrom, C. David
    Wheeler, David C.
    Langkilde, Anna Maria
    Heerspink, Hiddo J. L.
    LANCET DIABETES & ENDOCRINOLOGY, 2019, 7 (06): : 429 - 441
  • [10] Mechanisms underlying the blood pressure lowering effects of dapagliflozin, exenatide, and their combination in people with type 2 diabetes: a secondary analysis of a randomized trial
    Charlotte C. van Ruiten
    Mark M. Smits
    Megan D. Kok
    Erik H. Serné
    Daniël H. van Raalte
    Mark H. H. Kramer
    Max Nieuwdorp
    Richard G. IJzerman
    Cardiovascular Diabetology, 21
12345